Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + carfilzomib + pomalidomide + dexamethasone in newly diagnosed multiple myeloma with dialysis-dependent renal failure
2022-004207-32Phase 2Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, carfilzomib, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Medical University of Innsbruck. Primary endpoint: Renal recovery. Started Feb 2023; status: terminated.
02
Drugs
daratumumabcarfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-004207-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004207-32.